Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 886 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Linezolid found superior to treat MRSA: Study reports

The prospective double-blind controlled multicenter trial randomized hospitalized adult patients with hospital-acquired or healthcare-associated MRSA pneumonia to receive intravenous Linezolid (600 mg every 12 hours) or Vancomycin (15

Waters, Tecan enter clinical assay deal

Waters will make use of the technologies from both companies to combine into a single, fully-supported analytical system solution that helps laboratories increase assay throughput and efficiency, improve

Vivus reports Phase 3 study results of Avanafil

Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor, and is licensed from Mitsubishi Tanabe Pharma. The randomized double-blind placebo-controlled Revive (TA-301) trial of Avanafil enrolled 646

Dara acquires rights to sell Soltamox in US

The FDA-approved Soltamox is used primarily for the chronic treatment of breast cancer or for prevention in certain susceptible breast cancer subgroups. Under the terms of the merger

BTG Voraxaze secures FDA nod

Voraxaze is used to treat toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. The approval of Voraxaze was granted under priority

Celldex initiates patient dosing in CDX-301study

CDX-301 is soluble, recombinant human FMS-like tyrosine kinase 3 ligand (Flt3L) that stimulates the expansion and differentiation of hematopoietic progenitor and stem cells. The dose-escalating Phase 1 study

Teva UK introduces Latanoprost eye drops

Currently, Latanoprost is available as Xalatan (Latanoprost) from Pfizer, and is now introduced by Teva to fulfil generic prescriptions. Teva commercial director Kim Innes said this is the